


PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
is a collection of information unless it contains a valid OMB control number.

FORM PTO-1449 Commerce (Modified)		U.S. Department of Patent and Trademark Office		Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499			
<div style="border: 2px solid black; border-radius: 50%; padding: 10px; display: inline-block;"> U.S. PATENT AND TRADEMARK OFFICE NOV 17 2005 </div>				Applicant: John A. Kink <i>et al.</i>				
				Filing Date: 7/25/2003				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Group Art Unit: 1646				
(37 CFR § 1.98(b))								
U.S. PATENT DOCUMENTS								
Examiner Initials	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date		
X2	1	4,477,432	10/16/84	Hardie	424	85	4/05/82	
	2	5,604,231	2/18/97	Smith <i>et al.</i>	514	256	1/06/95	
	3	5,614,540	3/25/97	Christensen	514	362	5/18/95	
	4	5,654,407	8/05/97	Boyle <i>et al.</i>	530	388.15	5/05/95	
	5	5,436,154	7/25/95	Barbanti <i>et al.</i>	435	240.27	12/13/91	
	6	5,385,901	1/31/95	Kaplan <i>et al.</i>	514	231.5	10/02/92	
	7	4,870,163	9/26/89	Rubin <i>et al.</i>	530	43	8/29/85	
	8	5,656,272	8/12/97	Le <i>et al.</i>	424	133.1	2/04/94	
	9	4,676,982	6/30/87	Hassig	424	85	08/04/86	
	10	4,677,064	6/30/87	Mark <i>et al.</i>	435	68	5/02/85	
	11	4,748,018	5/31/88	Strolle <i>et al.</i>	424	87	6/19/84	
	12	5,080,895	1/14/92	Tokoro	424	85.8	4/01/91	
	13	5,487,984	1/30/96	Allet <i>et al.</i>	435	69.5	12/20/85	
	14	5,672,347	9/30/97	Aggarwal <i>et al.</i>	424	139.1	5/05/95	
	15	5,707,622	1/13/98	Fong <i>et al.</i>	424	145.1	3/01/95	
	16	5,753,228	5/19/98	Sterling <i>et al.</i>	424	151.1	12/05/94	
	17	5,772,999	6/30/98	Greenblatt <i>et al.</i>	424	187.1	7/30/96	
	18	5,795,967	8/18/98	Aggarwal <i>et al.</i>	530	388.23	6/07/95	
	19	5,420,253	5/30/95	Emery <i>et al.</i>	530	423	9/09/93	
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
X2	20	WO98/14209	04/09/98	PCT				
	21	WO96/33204	10/24/96	WIPO				
	22	WO97/15327	05/01/97	PCT				
	23	EP 0 155 549 B1	03/20/91	EPO				
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
X2	24	Polson <i>et al.</i> , "Antibodies to Proteins from Yolk of Immunized Hens," <i>Immunol. Comm.</i> , 9:495-514 (1980)						
	25	Okayasu <i>et al.</i> , "A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice," <i>Gastroenterology</i> , 98:694-702 (1990)						
	26	Kojouharoff <i>et al.</i> , "Neutralization of tumour necrosis facto (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice," <i>Clin. Exp. Immunology</i> , 107: 353-358 (1997)						
	27	Olson <i>et al.</i> , "Antiserum to Tumor Necrosis Factor and failure to Prevent Murine Colitis," <i>J. Pediatric Gastroenterology and Nutrition</i> 21: 410-418 (1995)						
	28	Stack <i>et al.</i> , "The Effects of CDP571, An Engineered Human IgG α 4 Anti-TNF α Antibody in Crohn's Disease", <i>Gastroenterology</i> , 110:A1018 (1996)						
Examiner: <i>Rigby</i>				Date Considered: 4/13/07				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 Commerce (Modified)		U.S. Department of Patent and Trademark Office		Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: John A. Kink <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 7/25/2003 Group Art Unit: 1646	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
X	29	Rutgeerts <i>et al.</i> , "Retreatment with Anti-TNF- α Chimeric Antibody (cA2) Effectively maintains cA3-Induced remission in Crohn's Disease," <i>Gastroenterology</i> 112:A1078 (1997)			
	30	Van Dulleman <i>et al.</i> , "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> 109:129-138 (1995)			
	31	Targan <i>et al.</i> , "A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease," <i>New England Journal of Medicine</i> , 337:1029-1035 (1997)			
	32	Plevy <i>et al.</i> , "A Role for TNF- α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease," <i>Journal of Immunology</i> , 6277-6282 (1997)			
	33	Sartor, "Current Concepts of the Etiology and Pathogenesis of Ulcerative Colitis and Crohn's Disease," <i>Inflammatory Bowel Disease</i> , 24:475-507 (1995)			
	34	Sartor, "Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases," <i>Gastroenterology</i> , 92:5S-11S (1997)			
	35	Robinson, "Optimizing Therapy for Inflammatory Bowel Disease," <i>American Journal of Gastroenterology</i> , 92:12-17 (1997)			
	36	Targan and Shanahan, "Pseudomembranous Colitis and Clostridium Difficile Infection," <i>Inflammatory Bowel Disease From Bench to Bench</i> , 51:743-755 (1994)			
	37	Ogorek and Fisher, "Differentiation Between Crohn's Disease and Ulcerative Colitis," in <i>Inflammatory Bowel Disease</i> , Katz, ed., 78:1249-1257 (1994)			
	38	Cameron, "Anti-TNF- α treatments set to mop up in rheumatoid arthritis," <i>Research and Development</i> , pp. 9-10 (1998)			
	39	Elliott <i>et al.</i> , "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>Lancet</i> , 344:1105-1110 (1994)			
	40	Elliott <i>et al.</i> , "Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis," <i>Lancet</i> 344:1125-1127 (1994)			
	41	Gibson, "Inflammatory Bowel Disease Current Concepts in Pathogenesis and Therapy," <i>Clin. Immunother.</i> , 2(2):135-160 (1994)			
	42	Bell and Wallace, "Inflammatory Bowel Disorders Current and Future Drugs that Modulate Adhesion Molecules," <i>Biodrugs</i> , 7(4):273-284 (1997)			
	43	Opal <i>et al.</i> , "Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock," <i>J. Infect. Dis.</i> , 173:1415-1421 (1996)			
	44	Russell <i>et al.</i> , "Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function," <i>J. Infect. Dis.</i> , 171:1528-1538 (1995)			
	45	Levine <i>et al.</i> , "Intravenous Immunoglobulin Therapy for Active, Extensive and Medically Refractory Idiopathic Ulcerative or Crohn's Colitis" <i>Am J Gastroenterol</i> , 87:91-100 (1992)			
	46	Neurath <i>et al.</i> , "Predominant Pathogenic role of Tumor Necrosis Factor in Experimental Colitis in Mice," <i>Eur J Immunol</i> 27:1743-1750 (1997)			
	47	Neurath <i>et al.</i> , "Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in mice," <i>J Exp Med</i> 182:1281-1290 (1995)			
	48	Feldmann <i>et al.</i> , "Cytokine Expression and Networks in Rheumatoid Arthritis: Rationale for Anti-TNF α Antibody Therapy and its Mechanism of Action," <i>J Inflammation</i> 47:90-96 (1996)			
	49	Reimund <i>et al.</i> , "Increased production of tumor necrosis factor- α , interleukin-1- β and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease" <i>Gut</i> 39:684-689 (1996)			
	50	Duchmann <i>et al.</i> , "Tolerance towards resistant intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12," <i>Eur J Immunol</i> 26:934-938 (1996)			
	51	Tsubokura <i>et al.</i> , "Oral administration of antibodies as prophylaxis and therapy in <i>Campylobacter jejuni</i> -infected chickens," <i>Clin Exp Immunol</i> 108:451-455 (1997)			
	52	Nicholls <i>et al.</i> , "Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea," <i>J Clin Path</i> 46:757-760 (1993)			
	53	Tjellström <i>et al.</i> , "Oral immunoglobulin treatment in Crohn's disease," <i>Acta Paediatr</i> 86:221-223 (1997)			
✓	54	Rubalteli <i>et al.</i> , "Prevention of necrotizing enterocolitis in neonates at risk by oral administration of monomeric IgG," <i>Dev Pharmacol Ther</i> 17:138-143 (1991)			
Examiner:		Date Considered: 4/13/07			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 Commerce (Modified)		U.S. Department of Patent and Trademark Office		Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: John A. Kink <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 7/25/2003	Group Art Unit: 1646
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
55	Armastron <i>et al.</i> , "Tumor necrosis factor and inflammatory bowel disease," <i>British Journal of Surgery</i> 84:1051-1058 (1997)				
56	Monteleone <i>et al.</i> , "Interleukin 12 (IL-12) is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells (LPMCs)," <i>Gastroenterology</i> 112:1169-1178 (1997)				
57	Starnes <i>et al.</i> , "Anti-IL-6 monoclonal antibodies protect against lethal <i>Escherichia coli</i> infection and lethal tumor necrosis factor-alpha challenge in mice" <i>J Immuno</i> 12:4185-4191 (1990)				
58	Doherty <i>et al.</i> , "Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha" <i>J Immuno</i> 5:1666-1670 (1992)				
59	Manthey <i>et al.</i> , "The role of cytokines in host responses to endotoxin" <i>Reviews in Med Microbio</i> 3:72-79 (1992)				
60	Dalekos, <i>et al.</i> , "High concentrations of soluble interleukin-2 receptors and interleukin-6 in active ulcerative cells" <i>Hellenic J Gastro</i> 8:319-327 (1995)				
61	Evans, <i>et al.</i> , "Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571" <i>Aliment Pharmacol Ther</i> 11:1031-1035 (1997)				
62	Hoang, <i>et al.</i> , "Symposium: Role of cytokines in inflammatory bowel disease" <i>Acte Gastro-Enterologica Belgica</i> 57:219-223 (1994)				
63	van Hogeand, <i>et al.</i> , "Selective immunomodulation in patients with inflammatory bowel disease-future therapy or reality?" <i>Netherlands J of Med</i> 48:64-67 (1996)				
64	Zacharchuk <i>et al.</i> , "Macrophage-mediated cytotoxicity: Role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor," <i>PNAS USA</i> 80:6341-6345 (1983)				
65	Zacharchuk, Charles Michael, "A Macrophage Cytotoxic Factor: Immunochemical and Functional Characterization," Dissertation Abstract (1983)				
66	Pennica <i>et al.</i> , "Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> 312:724-729 (1984)				
67	Ruff, Michael Roland, "Mechanism of Action of a Serum Oncolytic Protein, Rabbit Tumor Necrosis Factor," Dissertation Abstract. (1980)				
68	Beck <i>et al.</i> , "Cytokines in inflammatory bowel disease," <i>Mediators of Inflammation</i> 6:95-103 (1997)				
69					
70					
71					
72					
73					
74					
75					
76					
77					
78					
79					
Examiner: 		Date Considered: 4/13/07			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					